PMID- 38073872
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231211
IS  - 2434-0790 (Electronic)
IS  - 2434-0790 (Linking)
VI  - 5
IP  - 12
DP  - 2023 Dec 8
TI  - Periprocedural Thrombogenicity Change Is Associated With Subclinical Leaflet 
      Thrombosis Progression in Patients Undergoing Transcatheter Aortic Valve 
      Implantation.
PG  - 450-458
LID - 10.1253/circrep.CR-23-0092 [doi]
AB  - Background: Subclinical leaflet thrombosis occasionally occurs after 
      transcatheter aortic valve implantation (TAVI), but its exact etiology and 
      relationship with thrombogenicity remain unknown. Methods and Results: This study 
      enrolled 35 patients who underwent TAVI. Thrombogenicity was evaluated using a 
      total thrombus-formation analysis system (T-TAS) to compute the 
      thrombus-formation area under the curve (PL(18)-AUC(10) and AR(10)-AUC(30)). 
      Periprocedural thrombogenic parameters including T-TAS were investigated at 
      pre-TAVI, 2 days, 7 days, and 3 months post-TAVI. Hypoattenuated leaflet 
      thickening (HALT) and maximum leaflet thickness (MLT) were evaluated using 
      contrast-enhanced computed tomography 7 days and 3 months post-TAVI. The 
      associations between thrombogenicity and HALT or MLT were assessed. T-TAS 
      parameters consistently decreased at 2 and 7 days post-TAVI, followed by 
      improvement at 3 months. HALT was detected in 20% and 17% of patients at 7 days 
      and 3 months, respectively, post-TAVI. The median MLT value was 1.60 mm at 7 days 
      and 3 months post-TAVI. A significant positive correlation was observed between 
      the decrease in the AR(10)-AUC(30) and MLT at 7 days post-TAVI. Univariate linear 
      regression analysis revealed a decrease in the AR(10)-AUC(30) and an increase in 
      the D-dimer level as a significant predictor of MLT deterioration. Conclusions: 
      The findings suggested that a transient decrease in thrombogenicity following 
      TAVI predicts leaflet thrombosis, implying that monitoring thrombogenicity may be 
      useful for predicting progression of leaflet thrombosis.
CI  - Copyright (c) 2023, THE JAPANESE CIRCULATION SOCIETY.
FAU - Kuyama, Naoto
AU  - Kuyama N
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
FAU - Kaikita, Koichi
AU  - Kaikita K
AD  - Division of Cardiovascular Medicine and Nephrology, Department of Internal 
      Medicine, Faculty of Medicine, University of Miyazaki Miyazaki Japan.
FAU - Ishii, Masanobu
AU  - Ishii M
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
AD  - Department of Medical Information Science, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
FAU - Tabata, Noriaki
AU  - Tabata N
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
FAU - Oda, Seitaro
AU  - Oda S
AD  - Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto 
      University Kumamoto Japan.
FAU - Otsuka, Yasuhiro
AU  - Otsuka Y
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
FAU - Egashira, Koichi
AU  - Egashira K
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
FAU - Shirahama, Yuichiro
AU  - Shirahama Y
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
FAU - Hanatani, Shinsuke
AU  - Hanatani S
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
FAU - Takashio, Seiji
AU  - Takashio S
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
FAU - Matsuzawa, Yasushi
AU  - Matsuzawa Y
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
FAU - Yamamoto, Eiichiro
AU  - Yamamoto E
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
FAU - Hirai, Toshinori
AU  - Hirai T
AD  - Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto 
      University Kumamoto Japan.
FAU - Tsujita, Kenichi
AU  - Tsujita K
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University Kumamoto Japan.
AD  - Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences, 
      Kumamoto University Kumamoto Japan.
LA  - eng
PT  - Journal Article
DEP - 20231130
PL  - Japan
TA  - Circ Rep
JT  - Circulation reports
JID - 101746642
PMC - PMC10700031
OTO - NOTNLM
OT  - Hypoattenuated leaflet thickening
OT  - Subclinical leaflet thrombosis
OT  - TAVI
OT  - Thrombogenicity
COIS- K.K., K.T. are members of Circulation Reports' Editorial Team. K.K. received 
      Grants-in-Aid for Scientific Research (20K08451) from the Ministry of Education, 
      Culture, Sports, Science and Technology of Japan, received remuneration for 
      lectures from Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma AG., 
      Otsuka Pharmaceutical Co., Ltd., Bristol-Myers K.K., and Kowa Pharmaceutical Co. 
      Ltd., received trust research/joint research funds from Bayer Yakuhin, Ltd., and 
      Daiichi Sankyo Co., Ltd., and received scholarship funds from Abbott Medical Co., 
      Ltd. K.T. received significant research grants from Bayer Yakuhin, Ltd., 
      Bristol-Myers K.K., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., CSL 
      Behring K.K., JIMRO Co., Ltd., Alexion Pharmaceuticals, Inc., AnGes, Inc., 
      PPD-Shin Nippon Biomedical Laboratories K.K., SUGI BEE GARDEN (International) 
      Co., Ltd., Pfizer Japan Inc., scholarship funds from AMI Co., Ltd., Boehringer 
      Ingelheim Japan, Daiichi Sankyo Co., Ltd., ONO Pharmaceutical Co., Ltd., Otsuka 
      Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Abbott Medical Co., 
      Ltd., and ITI Co., Ltd. and honoraria from Amgen K.K., Abbott Medical Co., Ltd., 
      AstraZeneca K.K., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Medtronic Japan 
      Co., Ltd., Kowa Pharmaceutical Co. Ltd., Kyowa Kirin Co., Ltd., Novartis Pharma 
      K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Janssen 
      Pharmaceutical K.K., and belongs to endowed departments donated by Abbott Japan 
      Co., Ltd., Boston Scientific Japan K.K., Fides-one, Inc., GM Medical Co., Ltd., 
      ITI Co., Ltd., Kaneka Medix Co., Ltd., NIPRO Corporation, Terumo Co, Ltd., Abbott 
      Medical Co., Ltd., Fukuda Denshi Co., Ltd., Japan Lifeline Co., Ltd., and 
      Medtronic Japan Co., Ltd.
EDAT- 2023/12/11 06:45
MHDA- 2023/12/11 06:46
PMCR- 2023/11/30
CRDT- 2023/12/11 05:36
PHST- 2023/11/09 00:00 [received]
PHST- 2023/11/09 00:00 [accepted]
PHST- 2023/12/11 06:46 [medline]
PHST- 2023/12/11 06:45 [pubmed]
PHST- 2023/12/11 05:36 [entrez]
PHST- 2023/11/30 00:00 [pmc-release]
AID - 10.1253/circrep.CR-23-0092 [doi]
PST - epublish
SO  - Circ Rep. 2023 Nov 30;5(12):450-458. doi: 10.1253/circrep.CR-23-0092. eCollection 
      2023 Dec 8.